www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

CUDC-101

产品编号: D50766

CAS: 1012054-59-9

分子式: C24H26N4O4

纯度: ≥98%

InChi: InChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)

InChi Key: PLIVFNIUGLLCEK-UHFFFAOYSA-N

Smiles: COC1C=C2N=CN=C(NC3C=CC=C(C=3)C#C)C2=CC=1OCCCCCCC(=O)NO

外观: 固体粉末

作用通路: EGFR

溶解性: DMSO up to 100 mM

保存条件: Store in dry, dark place for one year.

产品介绍: CUDC-101 is a potent multi-target inhibitor targeting HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, respectively.It is specific for class I and class II HDACs, not for class III Sir-type HDACs, and has > 50-fold selectivity against other protein kinases. CUDC-101 displays broad antiproliferative activity in many human cancer cell types with IC50 of 0.04-0.80 μM, exhibiting a higher potency than erlotinib, lapatinib, and combinations of vorinostat with either erlotinib or lapatinib in most cases. It can inhibit EGFR and Her2 phosphorylation, reduce cell proliferation and induce apoptosis in HCC827 non-small cell lung cancer (NSCLC) xenografts. It inhibits EGFR and induces upregulation of acetylated histone H3 in a dosedependent fashion. In vivo CUDC-101 promotes tumor regression in various cancer xenograft models such as non-small cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. Currently it is in Phase I clinical trials for advanced head and neck, gastric, breast, liver and non-small cell lung cancer tumors.